Strategic Assessment for Portfolio Expansion of an Animal Health Pharma Company

A global animal health pharmaceutical client engaged Stellarix to gain end-to-end visibility into the nsMRA landscape relevant to feline chronic kidney disease (CKD). Our actionable intelligence enabled the firm to strengthen its competitive position by expanding its portfolio, streamlining partner shortlisting & prioritizing, and identifying market gaps.

Client Background:

A global animal health pharmaceutical company seeking to expand its renal disease portfolio by evaluating non-steroidal mineralocorticoid receptor antagonists (nsMRAs) for the treatment of feline chronic kidney disease (CKD) through strategic partnerships, licensing, or acquisition.

Engagement Objective:

The client wanted end-to-end visibility into the nsMRA landscape relevant to feline CKD, including:

• Identification of clinically relevant nsMRA assets aligned with animal health requirements
• Clear understanding of competitor pipelines, strategies, and differentiation
• Gain insights into partnership-ready companies and feasible collaboration models

Client Impact:

• Pipeline Expansion Enablement – Enabled the client to identify high-potential nsMRA assets suitable for repurposing or adaptation for feline CKD treatment.
• Partner Shortlisting & Prioritization – Delivered a curated list of life sciences companies open to collaboration, including assessment of partnership feasibility and strategic fit.
• Risk-Informed Decision Making – Linked clinical trial outcomes and safety profiles to sponsor strategies, supporting better risk assessment and asset prioritization.
• Competitive Positioning Clarity – Provided insight into competitor pipelines, innovation trends, and differentiation strategies, strengthening the client’s competitive roadmap.
• Market Gap Identification – Highlighted unmet needs and whitespace opportunities within the nsMRA landscape for feline CKD.

Outcome Snapshot: